openheart Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly?

James J DiNicolantonio,¹ Mark F McCarty²

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/openhrt-2018-000789>).

To cite: DiNicolantonio JJ, McCarty MF. Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly?. *Open Heart* 2018;5:e000789. doi:10.1136/openhrt-2018-000789

Accepted 21 March 2018

A number of prospective studies, dating back to the 1980s, have found that lower levels of plasma cholesterol correlate with increased risk for cancer; in some of these studies, it was noted that this correlation was strongest for cancers diagnosed within a year of cholesterol measurement, suggesting the possibility of reverse causality.^{1–11} More recently, Ravnskov and colleagues conducted a systematic review of cohort studies enrolling subjects over 60 in which the association of low-density lipoprotein cholesterol (LDL-C) with all-cause mortality and/or cardiovascular mortality had been evaluated.¹² In 14 of the 30 total cohorts involved, LDL-C was *inversely* and significantly associated with all-cause mortality; in the remaining 16, no association was found. With respect to cardiovascular mortality, which was determined in nine cohorts, the association of LDL-C was inverse and significant in two and null in seven. The failure to find a positive correlation between LDL-C and cardiovascular mortality is consistent with the previous research reporting that the positive correlation of LDL cholesterol and cardiovascular mortality that is clearly seen among younger subjects is substantially blunted among the elderly.

These findings have led some to suspect that low LDL-C plays a pathogenic role in cancer and perhaps other non-cardiovascular pathologies and that LDL-C is of little pathogenic significance for the progression atherogenic disease in the elderly.¹² This interpretation evidently casts doubt on the wisdom of medicating the elderly for LDL-C control.

COUNTERARGUMENTS DISPUTE THE PATHOGENICITY OF LOW LDL

The thesis that low LDL-C may play a causative role in higher non-cardiovascular mortality has been challenged cogently by several lines of evidence. Law and colleagues¹³ compared cohort studies of groups of employees, most

of whom could be presumed to be healthy at baseline, with community cohorts, which included many individuals with prevalent disease. They found that low total cholesterol in the employee cohorts was *not* associated with increased risk for non-cardiovascular mortality, whereas such an association *was* found in the community cohorts.¹³ They concluded that when low cholesterol correlated with increased risk in the community cohorts, this likely reflected reverse causation—an incipient disease state was responsible for a decline in plasma cholesterol. They did, however, confirm—as many others have^{14–18}—that low cholesterol is associated with increased risk for haemorrhagic stroke in those with elevated blood pressure; presumably, LDL impacts the risk for cerebral aneurysms, or the fragility of these aneurysms. Nonetheless, the protection from ischaemic vascular disease associated with low LDL-C more than outweighed the adverse impact on haemorrhagic stroke risk in these Western cohorts.

Iribarren and colleagues examined data from the prospective Honolulu Heart Study, segregating the subjects into groups according to whether their plasma cholesterol rose, fell or remained stable during the first 6 years of follow-up.¹⁹ They found that subjects with low cholesterol at baseline, whose cholesterol remained low during follow-up, experienced no increase in risk for non-cardiovascular mortality as compared with those with average cholesterol. However, individuals whose cholesterol fell from mid-range to low during the follow-up period *did* experience an increased risk for cancer death and for non-cardiovascular/non-cancer death. It should be noted that, inasmuch as this study examined cholesterol changes over the years 1965–1974, most of the reductions in cholesterol observed likely were spontaneous, as opposed to being achieved by hypolipidemic medication.

¹Mid America Heart Institute, Kansas, USA

²Catalytic Longevity, Encinitas, California, USA

Correspondence to

Dr James J DiNicolantonio; jjdinicol@gmail.com

The fear that statin therapy might increase cancer risk by lowering LDL-C has been put to rest by the outcomes of placebo-controlled clinical trials with statins. A meta-analysis of 27 statin treatment trials confirmed the expected reductions in major vascular events with statin therapy, while failing to note an effect of such therapy on risk for new cancer incidence or non-vascular mortality.²⁰ A significant reduction of all-cause mortality was seen in patients who had no history of vascular disease at baseline.

Of particular interest is a meta-analysis of randomised trials comparing statins with placebos in the management of hyperlipidemic elderly subjects (over 65 years of age).²¹ This found that, in the statin-treated group, risk for myocardial infarction and stroke was significantly reduced, a trend towards a reduction in all-cause death did not achieve statistical significance (RR=0.941, 95% CI 0.856 to 1.035), and incidence of new cancer was not influenced. These findings evidently refute the notion that LDL-C loses its pathogenicity for atherosclerotic progression in the elderly.

Perhaps the most conclusive evidence disputing a causal relationship between low LDL-C and cancer is provided by a Mendelian randomisation study examining the association between genetic polymorphisms associated with lower LDL-C and cancer risk. Importantly, although low LDL-C was strongly associated with increased cancer risk in the cohorts examined, none of the genotypes linked to lower LDL-C—some associated with LDL-C reductions as great as 38%—were associated with higher cancer risk.²² In marked contrast, Mendelian randomisation studies have concluded that elevated LDL-C has an even stronger impact on risk for cardiovascular disease than that reported in observational epidemiology (presumably reflecting the fact that a single measurement of LDL-C is a rather imprecise gauge of life-long LDL-C exposure).^{23 24} Mendelian randomisation likewise confirms that LDL-C remains a mediating risk factor for vascular disease in the oldest old.²⁵

It may also be noted that risks for so-called ‘Western’ cancers have been found to be comparatively quite low in quasi-vegan societies characterised by very low LDL-C levels.²⁶ This clearly speaks against low LDL-C playing an important role in the induction of such cancers. Moreover, coronary disease is a minor cause of death in such cultures.

Online supplementary Table 1 summarises the evidence suggesting that low LDL levels per se do not increase the risk of death from cancer or non-cardiovascular causes.

IL-6 PROMOTES LDL-C CATABOLISM BY UPREGULATING SYNTHESIS OF LDL RECEPTORS

The evident alternative possibility to low LDL-C being pathogenic is that low or decreasing LDL-C may simply be serving as a marker for a factor or factors that is the true cause of excess non-cardiovascular mortality. It has long been known that LDL-C in humans and primates often declines acutely in the context of inflammation

or trauma involving an acute-phase response—in the days following a myocardial infarction, for example.^{27–30} Indeed, studies with hepatocyte cultures show that interleukin (IL)-1 β , tumour necrosis factor- α (TNF α), IL-6 and other cytokines elevated during inflammation can increase hepatocyte expression of the LDL receptor.^{31 32} Whereas IL-1 β and TNF α do so by a mechanism involving modulation of intracellular cholesterol content, the effect of IL-6 in this regard is not dependent on cholesterol modulation.³² Nearly two decades ago, researchers reported that IL-6 increases the transcription of the LDL receptor gene, without altering the half-life of the transcript or of the resulting protein.³² This effect did not require new protein synthesis and was associated with increased binding of the transcription factors sterol regulatory element-binding protein (SREBP) 1a/SREBP2 and Sp1 to their respective response elements in the promoter of the LDL receptor gene; hence, IL-6 likely is either increasing intranuclear transport of these transcription factors, or altering their configuration post-translationally in a way that enhances their DNA binding.

That this effect is of physiological importance is demonstrated by clinical studies showing that administration of a monoclonal antibody targeting and abolishing the bioactivity of the IL-6 receptor, tocilizumab, leads to an increase in plasma LDL-C of about 15%–20% in patients with rheumatoid arthritis.^{33–35} This effect has been traced to a decrease in fractional catabolic rate for LDL particles that parallels the increases in LDL level, pointing to a decrease in LDL catabolism as the chief basis for the observed increase in LDL-C; moreover, tocilizumab was found to decrease the expression of LDL receptors on hepatocytes in vitro.^{34 35} In contrast, a controlled study enrolling patients who had experienced a previous myocardial infarct and who had elevated C-reactive protein (CRP) found that treatment with the IL-1 β -antagonist monoclonal antibody canakinumab did not influence LDL-C levels.³⁶ And controlled studies in which patients with rheumatoid arthritis or ankylosing spondylitis were treated with the TNF α -antagonist monoclonal infliximab have observed at most a modest or transitory impact on LDL-C.^{37–39} Hence, these findings suggest that IL-6 is likely to be the chief driver of the LDL-C reductions seen during acute phase responses.

IL-6 CORRELATES WITH INCREASED TOTAL MORTALITY IN THE ELDERLY

These findings have been complemented by reports that plasma IL-6 levels correlate positively with global mortality in the elderly. Very recently, a meta-analysis of nine prospective studies enrolling over 9000 elderly subjects found that, when comparing the upper and lower categories of IL-6 in these studies, relative risk for total mortality was 1.49 (95% CI 1.33 to 1.67) and for cardiovascular mortality was 1.69 (95% CI 1.27 to 2.25) in those with higher IL-6.⁴⁰ These findings were robust, holding up after adjustment for multiple covariants, and valid regardless of region or duration of

Figure 1 Prodromal syndromes decrease LDL-C via increased IL-6.

follow-up. Although this study did not examine the association of IL-6 with non-cardiovascular mortality per se, the fact that non-cardiovascular death was responsible for about two-thirds of overall mortality suggests that risk for non-cardiovascular mortality was about 40% higher among those in the upper category of IL-6 when compared with that in the lower category.

The thesis that the association between low LDL cholesterol and increased cancer risk is mediated by IL-6 is difficult to square with prospective epidemiology that often has failed to correlate plasma IL-6 with subsequent cancer risk; most though not all^{41–42} meta-analyses examining this association in specific cancers have failed to confirm such a correlation.^{43–47} However, a recent meta-analysis confirmed that increased CRP predicts increased overall cancer risk.⁴⁸ Most circulating CRP derives from the liver, and IL-6 is the primary stimulator of increased hepatic CRP production during an acute-phase response (although IL-1 β amplifies this response); marked decreases of CRP are seen during tocilizumab therapy.^{49–51} Hence, CRP might be viewed as a marker for IL-6 bioactivity in the liver, which is what drives down LDL levels. Perhaps single measurements of IL-6 provide a rather imprecise assessment of IL-6 signalling in the liver.

Hence, it seems reasonable to postulate that, when low LDL-C points to increased non-cardiovascular mortality, it is simply serving as a marker for incipient pathologies, associated with inflammatory elevation of IL-6, which are driving the increase in mortality risk (see figure 1). If this is the case, then, in multiple-regression analyses which correct for plasma IL-6 levels, the association between LDL-C and non-cardiovascular mortality will be substantially attenuated, if not eliminated. A small residual correlation might nonetheless remain, reflecting a role for other factors—such as a premorbid or depression-linked decline in dietary intake, LDL clearance by an incipient cancer or liver dysfunction—capable of lowering LDL-C.

IL-6 may also account for the loss of the positive association between LDL-C and cardiovascular risk noted in elderly populations. IL-6 levels tend to rise during the ageing process, even in the absence of evident infection or trauma; the greater incidence of abdominal obesity in the elderly, associated with macrophage activation in visceral fat, is likely partially responsible for this observation.^{52–55} Ershler has described IL-6 as ‘a cytokine for

gerontologists’.⁵² As noted, higher IL-6 levels are predictive of increased cardiovascular risk in the elderly; this may reflect a mediating role for IL-6 in cardiovascular disease, but IL-6 may also serve as a marker for inflammation in visceral fat and in atherosclerotic lesions.^{56–57} The ability of elevated IL-6 to drive down LDL-C in the elderly should therefore tend to mask the continuing pathogenic role of LDL-C in atherogenesis and vascular events.

CONCLUSION

Whereas there is good reason to suspect that low LDL levels may increase risk for haemorrhagic stroke in hypertensives—while providing substantial protection from atherothrombotic events—relatively low LDL-C in the elderly has also been linked epidemiologically to increased risk for cancer and for non-cardiovascular mortality. However, this association is not likely to be causative, for reasons summarised in the online Supplementary Table 1. A decline in LDL-C is typically seen during an acute-phase response associated with trauma or infection. One of the chief mediators of the acute-phase response is IL-6. IL-6 increases the transcription of LDL receptors in cultured hepatocytes; conversely, treatment of patients with rheumatoid arthritis with the IL-6-antagonist monoclonal antibody tocilizumab has been found to raise their LDL-C by slowing LDL catabolism. Since monoclonal antagonists of IL-1 β or of TNF α do not notably influence LDL-C, it is reasonable to conclude that IL-6 mediates the reduction of LDL-C observed during an acute-phase response. Importantly, meta-analysis has now confirmed that increased plasma IL-6 in the elderly is associated with a notable increase in all-cause and cardiovascular mortality; an increase in non-cardiovascular mortality can also be inferred from the data. Hence, it is proposed that when low LDL-C in the elderly predicts increased non-cardiovascular mortality, this low LDL-C is serving as a marker for inflammation-linked incipient pathologies, entailing increased production of IL-6, which are responsible for this increased mortality. This hypothesis can be tested in epidemiological studies that examine the association between LDL-C and mortality after statistical adjustment for IL-6 levels. It is further proposed that the age-related increase in IL-6 may explain, at least in part, the failure of LDL-C to correlate strongly with

cardiovascular risk in the elderly—even though, as statin trials in the elderly demonstrate, LDL-C continues to promote vascular disease in this group.

The authors used keyword searches on Pubmed to locate the data discussed in this essay.

Contributors Both authors contributed to the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests JJD is author of The Salt Fix.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Dyer AR, Stamler J, Paul O, *et al.* Serum cholesterol and risk of death from cancer and other causes in three Chicago epidemiological studies. *J Chronic Dis* 1981;34:249–60.
- Garcia-Palmeri MR, Sorlie PD, Costas R, *et al.* An apparent inverse relationship between serum cholesterol and cancer mortality in Puerto Rico. *Am J Epidemiol* 1981;114:29–40.
- Sorlie PD, Feinleib M. The serum cholesterol-cancer relationship: an analysis of time trends in the Framingham Study. *J Natl Cancer Inst* 1982;69:989–96.
- Morris DL, Borhani NO, Fitzsimons E, *et al.* Serum cholesterol and cancer in the hypertension detection and follow-up program. *Cancer* 1983;52:1754–9.
- Keys A, Aravanis C, Blackburn H, *et al.* Serum cholesterol and cancer mortality in the seven countries study. *Am J Epidemiol* 1985;121:870–83.
- Kromhout D, Bosschieter EB, Drijver M, *et al.* Serum cholesterol and 25-year incidence of and mortality from myocardial infarction and cancer. The Zutphen Study. *Arch Intern Med* 1988;148:1051–5.
- Knekt P, Reunanen A, Aromaa A, *et al.* Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. *J Clin Epidemiol* 1988;41:519–30.
- Schatzkin A, Hoover RN, Taylor PR, *et al.* Serum cholesterol and cancer in the NHANES I epidemiologic followup study. National Health and Nutrition Examination Survey. *Lancet* 1987;2:298–301.
- Law MR, Thompson SG. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. *Cancer Causes Control* 1991;2:253–61.
- Pekkanen J, Nissinen A, Punsar S, *et al.* Short- and long-term association of serum cholesterol with mortality. The 25-year follow-up of the Finnish cohorts of the seven countries study. *Am J Epidemiol* 1992;135:1251–8.
- Strasak AM, Pfeiffer RM, Brant LJ, *et al.* Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study. *Ann Oncol* 2009;20:1113–20.
- Ravnskov U, Diamond DM, Hama R, *et al.* Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. *BMJ Open* 2016;6:e010401.
- Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. *BMJ* 1994;308:373–9.
- Yang N, Lin M, Wang BG, *et al.* Low level of low-density lipoprotein cholesterol is related with increased hemorrhagic transformation after acute ischemic cerebral infarction. *Eur Rev Med Pharmacol Sci* 2016;20:673–8.
- Valappil AV, Chaudhary NV, Praveenkumar R, *et al.* Low cholesterol as a risk factor for primary intracerebral hemorrhage: A case-control study. *Ann Indian Acad Neurol* 2012;15:19–22.
- Goldstein LB, Amarenco P, Szarek M, *et al.* Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. *Neurology* 2008;70(24 Pt 2):2364–70.
- Sturgeon JD, Folsom AR, Longstreth WT, *et al.* Risk factors for intracerebral hemorrhage in a pooled prospective study. *Stroke* 2007;38:2718–25.
- Bang OY, Saver JL, Liebeskind DS, *et al.* Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. *Neurology* 2007;68:737–42.
- Iribarren C, Reed DM, Chen R, *et al.* Low serum cholesterol and mortality. Which is the cause and which is the effect? *Circulation* 1995;92:2396–403.
- Mihaylova B, Emberson J, Blackwell L, *et al.* The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012;380:581–90.
- Savarese G, Gotto AM, Paolillo S, *et al.* Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. *J Am Coll Cardiol* 2013;62:2090–9.
- Benn M, Tybjaerg-Hansen A, Stender S, *et al.* Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. *J Natl Cancer Inst* 2011;103:508–19.
- Ference BA, Yoo W, Alesh I, *et al.* Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. *J Am Coll Cardiol* 2012;60:2631–9.
- Holmes MV, Asselbergs FW, Palmer TM, *et al.* Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J* 2015;36:539–50.
- Postmus I, Deelen J, Sedaghat S, *et al.* LDL cholesterol still a problem in old age? A Mendelian randomization study. *Int J Epidemiol* 2015;44:604–12.
- McCarty MF, Insulin MMF. Insulin and IGF-I as determinants of low "Western" cancer rates in the rural third world. *Int J Epidemiol* 2004;33:908–10.
- Carpentier YA, Scruel O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. *Curr Opin Clin Nutr Metab Care* 2002;5:153–8.
- Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. *J Am Coll Cardiol* 1993;22:933–40.
- Sammalkorpi K, Valtonen V, Kerttula Y, *et al.* Changes in serum lipoprotein pattern induced by acute infections. *Metabolism* 1988;37:859–65.
- Akgün S, Ertel NH, Mosenthal A, *et al.* Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. *J Lab Clin Med* 1998;131:103–8.
- Stopeck AT, Nicholson AC, Mancini FP, *et al.* Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. *J Biol Chem* 1993;268:17489–94.
- Gierens H, Nauck M, Roth M, *et al.* Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. *Arterioscler Thromb Vasc Biol* 2000;20:1777–83.
- Kawashiri SY, Kawakami A, Yamasaki S, *et al.* Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. *Rheumatol Int* 2011;31:451–6.
- Strang AC, Bisioendial RJ, Kootte RS, *et al.* Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. *Atherosclerosis* 2013;229:174–81.
- Robertson J, Porter D, Sattar N, *et al.* Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. *Ann Rheum Dis* 2017;76:1949–52.
- Ridker PM, Everett BM, Thuren T, *et al.* Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;377:1119–31.
- Kiortsis DN, Mavridis AK, Filippatos TD, *et al.* Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. *J Rheumatol* 2006;33:921–3.
- Spanakis E, Sidiropoulos P, Papadakis J, *et al.* Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. *J Rheumatol* 2006;33:2440–6.
- Dahlqvist SR, Engstrand S, Berglin E, *et al.* Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. *Scand J Rheumatol* 2006;35:107–11.
- Li H, Liu W, Xie J. Circulating interleukin-6 levels and cardiovascular and all-cause mortality in the elderly population: a meta-analysis. *Arch Gerontol Geriatr* 2017;73:257–62.
- Heikkilä K, Harris R, Lowe G, *et al.* Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. *Cancer Causes Control* 2009;20:15–26.
- Kakourou A, Koutsoumpa C, Lopez DS, *et al.* Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies. *Cancer Causes Control* 2015;26:1449–60.
- Zhou B, Liu J, Wang ZM, *et al.* C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. *PLoS One* 2012;7:e43075.
- Poole EM, Lee IM, Ridker PM, *et al.* A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis

- factor α receptor 2 levels and risk of ovarian cancer. *Am J Epidemiol* 2013;178:1256–64.
45. Joshi RK, Lee SA. Obesity related adipokines and colorectal cancer: a review and meta-analysis. *Asian Pac J Cancer Prev* 2014;15:397–405.
 46. Zhou B, Shu B, Yang J, *et al.* C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. *Cancer Causes Control* 2014;25:1397–405.
 47. Zeng F, Wei H, Yeoh E, *et al.* Inflammatory markers of CRP, IL6, TNF α , and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies. *Cancer Epidemiol Biomarkers Prev* 2016;25:1231–9.
 48. Guo YZ, Pan L, Du CJ, *et al.* Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. *Asian Pac J Cancer Prev* 2013;14:243–8.
 49. Nishikawa T, Hagihara K, Serada S, *et al.* Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 α is essential for cytokine-driven C-reactive protein gene expression. *J Immunol* 2008;180:3492–501.
 50. Zhang D, Sun M, Samols D, *et al.* STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. *J Biol Chem* 1996;271:9503–9.
 51. Kojima T, Yabe Y, Kaneko A, *et al.* Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. *Mod Rheumatol* 2013;23:977–85.
 52. Ershler WB. Interleukin-6: a cytokine for gerontologists. *J Am Geriatr Soc* 1993;41:176–81.
 53. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. *Annu Rev Med* 2000;51:245–70.
 54. Maggio M, Guralnik JM, Longo DL, *et al.* Interleukin-6 in aging and chronic disease: a magnificent pathway. *J Gerontol A Biol Sci Med Sci* 2006;61:575–84.
 55. Mohammadi M, Gozashti MH, Aghadavood M, *et al.* Clinical significance of serum IL-6 and TNF- α levels in patients with metabolic syndrome. *Rep Biochem Mol Biol* 2017;6:74–9.
 56. Swerdlow DI, Holmes MV, Kuchenbaecker KB, *et al.* The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet* 2012;379:1214–24.
 57. Bacchiega BC, Bacchiega AB, Usnayo MJ, *et al.* Interleukin 6 inhibition and coronary artery disease in a high-risk population: a prospective community-based clinical study. *J Am Heart Assoc* 2017;6:e005038.